Alliqua Biomedical (ALQA) Lowered to Neutral at HC Wainwright

Alliqua Biomedical (NASDAQ:ALQA) was downgraded by HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued to investors on Monday, January 8th, Marketbeat.com reports. They currently have a $2.80 price target on the stock, down from their prior price target of $4.50. HC Wainwright’s target price indicates a potential upside of 31.46% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. ValuEngine upgraded shares of Alliqua Biomedical from a “sell” rating to a “hold” rating in a report on Friday, October 6th. Zacks Investment Research upgraded shares of Alliqua Biomedical from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a report on Tuesday, September 12th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Alliqua Biomedical presently has a consensus rating of “Hold” and a consensus target price of $8.20.

Alliqua Biomedical (NASDAQ:ALQA) opened at $2.13 on Monday. Alliqua Biomedical has a 52 week low of $1.73 and a 52 week high of $8.50.

Alliqua Biomedical (NASDAQ:ALQA) last issued its earnings results on Thursday, November 9th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.76). Alliqua Biomedical had a negative net margin of 155.55% and a negative return on equity of 110.42%. equities research analysts anticipate that Alliqua Biomedical will post -3.85 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Alliqua Biomedical (ALQA) Lowered to Neutral at HC Wainwright” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/01/alliqua-biomedical-alqa-downgraded-to-neutral-at-hc-wainwright.html.

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply